This report aims to provide detailed insights
into the global epigenetics
market. It provides valuable information on the
type, procedure, application, and region in the market. Furthermore, the
information for these segments, by region, is also presented in this report.
Leading players in the market are profiled to study their product offerings and
understand the strategies undertaken by them to be competitive in this market.
Expected
Revenue Growth Analysis:
The Epigenetics Market is projected to reach USD 1,605.7 million by 2022
from an estimated USD 854.0 million in 2017, at a CAGR of 13.5%
during the forecast period.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
Key Factors Driving Market Growth:
The growth in epigenetics market is primarily attributed to decreasing
sequencing costs, increasing research activity, funding for epigenetics research,
rising prevalence of cancer and growing applications of epigenetics in
non-oncology diseases. Expanding application areas of epigenetics in
non-oncology diseases, personalized medicine, and target therapy are expected
to provide growth opportunities for players operating in the market in the
coming years.
Kits Segment Accounted for the Largest Share of the Global Market,
by Product
On the basis of product, the kits segment accounted for the largest share of
the Global Epigenetics Market in 2016. This can be attributed to the fact that
a large number of kits are used in various epigenetic techniques. The rising
prevalence of a number of diseases, increasing R&D spending, and increased
government funding for life science research are the other factors expected to
support DNA
methylation market growth.
Among the Application Segments, Oncology Dominated the DNA Methylation
Market
Based on application, the oncology segment accounted for the largest share of
the Epigenetics Market in 2016. The large share of this segment can be
attributed to the rising prevalence of cancer and the increasing number of
research-related activities.
DNA Methylation Segment Dominated the Epigenetics Market, by
Technology
On the basis of technology, the Epigenetics Market is segmented into DNA
methylation, histone modifications, and other technologies (includes non-coding
RNA and chromatin remodeling). The DNA methylation segment accounted for the
largest share of the Global Epigenetics Market in 2016. The large share of this
segment is attributed to the increasing incidence of cancer and the ability of
this technique to study different types of cancer with quality outcomes.
North America Dominated the Global Epigenetics Industry
North America accounted
for the largest share of the DNA Methylation Market in 2016, followed by Europe. Increase in
epigenetics research activities, favorable government funding initiatives, high
R&D expenditure, rising incidence of various diseases, and the presence of
key players in the region are the key factors driving the growth of the
Epigenetics Industry in North
America.
Request Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=896
The major players in the Global Epigenetics Market are Illumina (US), Thermo Fisher (US),
Diagenode (Belgium),
QIAGEN (US), Merck Millipore (US), Abcam (UK), Active Motif (US), New England
Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad
(US).
Illumina dominated the global DNA Methylation
Market in 2016. The company
provides sequencing and array-based solutions for genetic analysis. It
develops, manufactures, and markets integrated systems and life science tools
for the analysis of genetic variation and biological function. Illumina
operates through 26 subsidiaries located in the US, the UK, and other countries
in Europe and the Asia Pacific regions. In order to achieve high growth and
increase its customer base, the company focuses on organic and inorganic
strategies such as product launches, collaborations, and agreements.